Successful development of future targeted therapies will require the flexibility to rapidly evaluate combination regimens involving new targeted agents in a single development program. The FDA has therefore developed draft guidance on drug co-development.
No takes yet. Share an insight, caveat, or question.
Woodcock et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: